SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Ayşegül Gündüz, Aslı Gündoğdu Eken, Başar Bilgiç, Hasmet A. Hanagasi, Kaya Bilgüvar, Murat Günel, A. Nazlı Başak, Sibel Ertan, FBXO7–R498X mutation: Phenotypic variability from chorea to early onset parkinsonism within a family, Parkinsonism & Related Disorders, 2014, 20, 11, 1253

    CrossRef

  2. 2
    Helen Ling, Igor Petrovic, Brian L. Day, Andrew J. Lees, Smoking-induced transient motor deterioration in a levodopa-treated patient with Parkinson’s disease, Journal of Neurology, 2012, 259, 11, 2419

    CrossRef

  3. 3
    Claire Thiriez, Gabriel Villafane, Frédérique Grapin, Gilles Fenelon, Philippe Remy, Pierre Cesaro, Can nicotine be used medicinally in Parkinson’s disease?, Expert Review of Clinical Pharmacology, 2011, 4, 4, 429

    CrossRef

  4. 4
    Coro Paisán-Ruiz, Rocio Guevara, Monica Federoff, Hasmet Hanagasi, Fardaz Sina, Elahe Elahi, Susanne A. Schneider, Petra Schwingenschuh, Nin Bajaj, Murat Emre, Andrew B. Singleton, John Hardy, Kailash P. Bhatia, Sebastian Brandner, Andrew J. Lees, Henry Houlden, Early-onset L-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations, Movement Disorders, 2010, 25, 12
  5. 5
    Peter Dome, Judit Lazary, Miklos Peter Kalapos, Zoltan Rihmer, Smoking, nicotine and neuropsychiatric disorders, Neuroscience & Biobehavioral Reviews, 2010, 34, 3, 295

    CrossRef

  6. 6
    Maryka Quik, Luping Z. Huang, Neeraja Parameswaran, Tanuja Bordia, Carla Campos, Xiomara A. Perez, Multiple roles for nicotine in Parkinson's disease, Biochemical Pharmacology, 2009, 78, 7, 677

    CrossRef

  7. 7
    Maryka Quik, Kathryn O'Leary, Caroline M. Tanner, Nicotine and Parkinson's disease: Implications for therapy, Movement Disorders, 2008, 23, 12